Results 111 to 120 of about 1,925 (192)

Análisis retrospectivo de la epidemiología, gravedad y evolución clínica de la bronquiolitis en la Unidad de Cuidados Intensivos Pediátricos: antes y después de Nirsevimab. [PDF]

Introducción: La introducción de Nirsevimab ha supuesto un cambio en el paradigma de la bronquiolitis por virus respiratorio sincitial (VRS).Objetivos: Analizar la epidemiología, incidencia y gravedad de los pacientes ingresados por bronquiolitis en la ...
Ramos Fuentes, Feliciano, Hernando Larroy, Alicia, García Íñiguez, Juan Pablo   +2 more
core  

Evaluating respiratory syncytial virus immunization strategies for infants in Canada: A cost-utility analysis. [PDF]

PLoS One
Gebretekle GB, Lan M, Xi M, Ximenes R, Buchan SA, Abrams EM, Andrew MK, Brousseau N, Killikelly A, Money D, Papenburg J, Rafferty E, Robinson JL, Siu W, Tunis M, Tuite AR.   +15 more
europepmc   +1 more source

Efficacy and effectiveness of long-acting monoclonal antibodies and vaccines against RSV: a systematic review and meta-analysis of studies from 2018 to 2025. [PDF]

EClinicalMedicine
Du J, Li S, Hung IFN, Wu JT, Leung K.
europepmc   +1 more source

Hypotonia and Lethargy as Potential Adverse Effect to Nirsevimab Administration in a Newborn Infant. [PDF]

J Pediatr Pharmacol Ther
Molina VMV, Mallo MN, Del Río ST, López-Ortego P, Solís-García G.   +4 more
europepmc   +1 more source

Epidemiological Impact of Nirsevimab on Admissions for Bronchiolitis in a Pediatric Emergency Department: A Single-Center Cohort Study. [PDF]

Viruses
Castagno E, Aschieri C, Ferri I, El Khbazi S, Milani L, Comoretto RI, Raffaldi I, Tardivo I, Spada M, Bondone C, Fagioli F.   +10 more
europepmc   +1 more source

Nirsevimab Immunization to Prevent Pediatric RSV Hospitalizations.

JAMA Pediatr
Attaianese F, Carreras G, Trapani S, Alberti I, Aricò M, Attanasi M, Bertolucci G, Bressan S, Caselli D, Casotto V, Cazzato S, Chiarelli F, Felici E, Frusciante A, Galeone MA, Garazzino S, Giannattasio A, Gitto E, Guerriero A, Guida F, Iudica G, Lanari M, Mandato C, Manzini A, Martelli G, Milani GP, Moriondo M, Notarangelo LD, Nunziata F, Pellegrino R, Peroni D, Piccotti E, Ponticiello E, Ricci S, Rulli I, Savoia F, Silvestro E, Sisto A, Soro F, Tonetto S, Zago A, Dani C, Azzari C, Indolfi G.   +43 more
europepmc   +1 more source

Real-world effectiveness of nirsevimab against RSV hospitalisation in infants during a season with low coverage and delayed circulation in Beijing, China: a population-based retrospective cohort study. [PDF]

Lancet Reg Health West Pac
Li J, Suo L, Wei L, Cao Z, Lu F, Xu H, Luo J, Shen Y, Gao P, Wu D, Feng Z, Yu R, Guo M, Wang Q, Yang P.   +14 more
europepmc   +1 more source

Health care utilization and cost implications of Chile's 2024 nirsevimab strategy for RSV prevention: a counterfactual analysis. [PDF]

Lancet Reg Health Am
Sauré D, Zgheib A, Torres JP, Goic M, Thraves C, Pacheco J, Burgos J, Del Solar F, Neira I, O'Ryan M, Basso LJ.   +10 more
europepmc   +1 more source

Broadly neutralizing nanobodies target a defined structural pivot site on the RSV fusion protein. [PDF]

EMBO Mol Med
Wang Q, Ke X, Li E, Hong D, Cheng Z, Li H, Zhang J, Jin T, Gong R, Shu B, Chiu S.   +10 more
europepmc   +1 more source

Understanding real-world effectiveness of nirsevimab and the characteristics of breakthrough RSV infections: a study protocol of individual-participant-level data meta-analysis (the GEMINI study). [PDF]

BMJ Open Respir Res
Ren S, Zhang H, Deng S, Nair H, Li Y.
europepmc   +1 more source